Trasplante autológo de células madre hematopoyéticas en pacientes con diagnóstico de neuroblastoma de alto riesgo en la Fundación Valle del Lili, Cali - Colombia

Yaris N, Mandiracioglu A, Büyükpamukcu M. Childhood cancer in developing countries. Pediatr Hematol Oncol. 2004;21:237-53.

https://doi.org/10.1080/08880010490276971

Lanzkowsky P, Jeffrey Lipton J, Fish J. Manual of pediatric hematology and oncology. 6th Edition Academic Press; 2016.

Registro Poblacional de Cáncer de Cali. Sistema de vigilancia epidemiológica de cáncer pediátrico para la ciudad de Cali [internet]. Cali, Colombia: Universidad del Valle; 2010. Disponible en: http://rpcc.univalle.edu.co/Estadisticas_uicc/Estadisticas/index.php?accion=seleccionar_estadistica&categoria=4

Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-77.

https://doi.org/10.1200/JCO.1993.11.8.1466

Lacayo N, Davis K. Pediatric Neuroblastoma Treatment & Management. Medscape; 2015. Disponible en: http://emedicine.medscape.com/article/988284-treatment

Matthay KK, Villablanca JG, Seeger RC. Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow trasplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-73.

https://doi.org/10.1056/NEJM199910143411601

Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer. 2013;119:665-71.

https://doi.org/10.1002/cncr.27783

Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugières L, Delgado R, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999;23:789-95.

https://doi.org/10.1038/sj.bmt.1701737

Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H, Le Teuff G, et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer. 2014;61:977-81,

https://doi.org/10.1002/pbc.24713

Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61:113-23.

https://doi.org/10.1007/s00280-007-0455-2

Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. J Oncology Journal. 2003;98:2274-81.

https://doi.org/10.1002/cncr.11773

Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, et al. CLINICAL PRACTICE GUIDELINES SIOP-PODC Adapted Risk Stratification and Treatment Guidelines: Recommendations for Neuroblastoma in Low- and Middle-Income Settings. Pediatr Blood Cancer. 2015;62:1305-16.

https://doi.org/10.1002/pbc.25501

Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14:999-1008.

https://doi.org/10.1016/S1470-2045(13)70309-7

Gomez S, Martinez M, Schuttenberg V, Cuello F, Costa A, Fomisano S, Fernandez R. Trasplante autologo (ATPH) de progenitores hematopoyéticos en niños con neuroblastoma. Servicio de hematología Hospital de niños de la plata. Revista Argentina de Hematología. 2005;9:82.

Guía de tratamiento Neuroblastoma alto riesgo 2014. Sociedad Argentina de Hemato-Oncología Pediátrica (SAHOP), Grupo de América Latina de Oncología Pediátrica (GALOP). Hospital de pediatria Prof. Dr. Juan P. Garrahan.

Proust-Houdemont S, Pasqualini C, Blanchard P, Dufour C, Benhamou E, Goma G, et al. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. Bone Marrow Transplant. 2016;51:1076-81,

https://doi.org/10.1038/bmt.2016.75

Yalc¸in B, Kremer LCM, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2015:CD006301,

https://doi.org/10.1002/14651858.CD006301.pub4

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016;7:4155-66,

https://doi.org/10.18632/oncotarget.6393

Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007-13, Epub 2009 Jan 26.

https://doi.org/10.1200/JCO.2007.13.8925

Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. J Clin Oncol. 2016;34 suppl; abstr-LBA3.

https://doi.org/10.1200/JCO.2016.34.18_suppl.LBA3